Review
Open access
Aug 2026
Impact of Mavacamten in the treatment of hypertrophic cardiomyopathy
Introduction: Hypertrophic cardiomyopathy is a genetic disease characterized by left ventricular hypertrophy and, in some patients, left ventricular outflow tract obstruction. Mavacamten is a primary cardiac myosin inhibitor that reduces hypercontractility, decreases actin-myosin cross-bridge formation, and promotes mo...
Karen Jessica Pilatasig Bazurto, Millie Tiffani León Jiménez, Edison Humberto Ruiz Intriago et al.
· Sage Sphere International Jo... · 0 citations